SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Senti Biosciences Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.23+0.00 (+0.84%)
Close on Oct 19, 2026
- Market cap
- $7.06M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2025
Operating margin
-312631.8%
Net margin
-279263.6%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | -82.7% | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -393.4% | |
| Return on assets | – | – | -82.4% | |
| Current ratio | – | – | 1.67 | |
| Capex to revenue | – | – | 890.9% | |
| Diluted shares | – | – | 22M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Senti Biosciences generated $206.77M from operations and spent $59.18M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$206.77M
Used
$59.18M
Capital expenditure$59.18M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-279263.6%
×Asset turnover0.00×
×Equity multiplier4.77×
=Return on equity, FY2025-393.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -279263.6% | 0.00× | 4.77× | -393.4% |
| FY2023 | -2774.6% | 0.02× | 1.55× | -73.2% |
| FY2022 | -1358.1% | 0.03× | 17.56× | -736.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$61.44M
- Cash generatingOperating cash flow above zero-$43.44M
- Return on assets improvedROA up on the prior year-44.2% → -62.8%
- Earnings backed by cashOperating cash flow above net income-$43.44M vs -$61.44M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.49 → 1.67
- No dilutionShare count did not rise5M → 22M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00